T-DXd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerSolid TumorOvarian CancerDrugHER2 PositiveNon-Squamous NSCLC

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

T-DXd

Daiichi Sankyo

Phase 3

62

Lexiscan

Astellas

Preclinical

13

Voltaren

Novartis

Preclinical

14

Methylthioninium Chloride

PProvepharm SAS

Preclinical

35

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

16

Tricor

JJagotec

Preclinical

17

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

18

Vfend

PPrism Pharmaceuticals

Preclinical

—9

Ablavar

LLantheus Medical Imaging

Preclinical

210

Naltrexone/bupropion

Novo Nordisk

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer6 trials

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

Recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT07371585·300 enrolled

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

Recruiting·FFudan University·Phase 1/2·NCT07134153·139 enrolled

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07417241·100 enrolled

Show 3 more trials

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

Completed·TThe First Affiliated Hospital with Nanjing Medical University··NCT07108595·142 enrolled

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06548178·242 enrolled

Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan - MARGARET Trial

Not yet recruiting·Mario Negri Institute for Pharmacological Research·Phase 3·NCT07828054·244 enrolled

HER2 Positive2 trials

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Unknown status·—··NCT06135194·30 enrolled

A Phase Ib/II Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer

Not yet recruiting·TThe Methodist Hospital Research Institute·Preclinical·NCT07785856·27 enrolled

Solid Tumor2 trials

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Active, not recruiting·Daiichi Sankyo·Phase 1·NCT06244485·210 enrolled

A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors

Recruiting·Daiichi Sankyo·Phase 1·NCT05765851·108 enrolled

Drug1 trial

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Recruiting·Daiichi Sankyo·Phase 3·NCT06174987·50 enrolled

Non-squamous NSCLC1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Recruiting·AstraZeneca·Phase 1·NCT04686305·244 enrolled

1 more indication

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active, not recruiting·Daiichi Sankyo·Preclinical·NCT04644068·702 enrolled

Details

Drug Info

Related News